NOTE: ALL STOCKS IN THIS WATCHLIST ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE. ANY TECHNICAL ANALYSIS IS PROVIDED IN THE CHART. PLEASE DO YOUR OWN DUE DILIGENCE BEFORE CONSIDERING INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com).
Stocks highlighted in this watchlist include: $CRMD, $CLSN, $ZSAN, IMNP
CRMD: Float of 56.31 million shares. According to Veer Mallick of Simply Wall St., CRMD is still trading at a fairly cheap price. In this instance, I’ve used price-to-book ratio (PB) ratio given that there is not enough information to reliably forecast the stock’s cash flows, and its earnings doesn’t seem to reflect its true value. I find that CRMD’s ratio of 2.5x is below its peer average of 4.8x, which suggests the stock is undervalued compared to the pharmaceuticals industry. If you’ve been keeping tabs on CRMD for some time, but hesitant on making the leap, I recommend you dig deeper into the stock. Given its current undervaluation, now is a great time to make a decision.
CLSN: Small float of 7.32 million shares with 10.45% short. A short squeeze could be coming up soon. From Zacks Equity Research, Celsion Corporation CLSN, a small biotech company, announced data from an early stage study on its immunotherapy candidate, GEN1, showing evident biological activity in newly diagnosed stage III and IV ovarian cancer. The study evaluated the drug in combination with neoadjuvant chemotherapy followed by an interval debulking surgery. The candidate has achieved a 100% disease control rate in patient population.
ZSAN: Float of 34.71 million shares with a large 13.74% short. A short squeeze will send the price rocketing up. ACCESSWIRE today issues a good research report on Zosano Pharma Corporation.
IMNP: A float of 9.7 million shares with 11.12% short. Here come a squeeze. On October 6th, the company announced it is Exiting Oncology in order to Narrow Its Focus on Two Promising Drugs. The company is conducting two Phase II clinical trials to test its lead drug candidate, bertilimumab, in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. On September 27th, 2017, IMNP announced positive results from its ongoing Phase II Trial of Bertilimumab in bullous pemphigoid. These promising preliminary results support the company's strategy of focusing its human capital and financial resources on its bertilimumab and NanoCyclo product candidates while streamlining operations by divesting its unrelated oncology business.
On Wednesday, the company announced that the results of a study investigating the therapeutic effect of oral and parenteral administration of anti-eotaxin-1 antibodies in an animal model of immune-mediated hepatitis will be presented at The Liver Meeting 2017 – the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) taking place October 20-24, 2017 in Washington, DC.